Please check your internet connection and try again.
# Megestrol Acetate
## Overview
Megestrol acetate is a synthetic derivative of progesterone. It is a potent progestin with antineoplastic and antiestrogenic effects.
## Primary Indications
* **Cachexia, anorexia, or unexplained significant weight loss:** Associated with acquired immunodeficiency syndrome (AIDS) or cancer.
* **Endometrial carcinoma:** Advanced disease, often in combination with other treatments.
## Adult Dosing
* **Weight loss/Cachexia:**
* Initial: 800 mg orally once daily.
* Some studies have used lower doses (e.g., 400 mg/day). Dosing may be adjusted based on patient response and tolerance.
* **Endometrial carcinoma:**
* 40 mg orally four times daily (160 mg/day).
* Higher doses of up to 800 mg/day may be used.
## Pediatric Dosing
There is no established pediatric dosing for megestrol acetate. Its use in pediatric populations is generally not recommended due to limited data and potential safety concerns.
## Dose Adjustments
* **Hepatic Impairment:** No specific guidelines, but caution is advised due to hepatic metabolism.
* **Renal Impairment:** No specific guidelines.
## Contraindications
* Known or suspected pregnancy.
* Known hypersensitivity to megestrol acetate or any component of the formulation.
* Use in patients with a history of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism) may be a relative contraindication, depending on the indication and risk-benefit assessment.
## Adverse Effects
* **Common:** Weight gain, increased appetite, hypertension, hot flashes, dyspnea, rash, diarrhea, nausea, abdominal pain, sexual dysfunction.
* **Serious:** Thromboembolic events (e.g., DVT, PE, stroke, myocardial infarction), adrenal insufficiency (especially with abrupt withdrawal after prolonged use), hyperglycemia, tumor flare.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** May decrease plasma concentrations of megestrol acetate. Monitor for reduced efficacy.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase plasma concentrations of megestrol acetate. Use with caution and monitor for adverse effects.
* **Corticosteroids:** Concurrent use may increase the risk of adverse effects.
## Monitoring
* **Weight and appetite:** Regularly assess for effectiveness.
* **Blood pressure:** Monitor for hypertension.
* **Signs and symptoms of thromboembolic events:** Educate patients to report chest pain, shortness of breath, leg swelling, or severe headache.
* **Electrolytes:** Monitor, especially in patients with significant fluid shifts or compromised renal function.
* **Blood glucose:** Monitor in patients with diabetes or risk factors for hyperglycemia.
* **Adrenal function:** Consider monitoring, particularly if long-term use is contemplated or if abrupt discontinuation is considered.
## Clinical Pearls
* Megestrol acetate can cause significant weight gain and fluid retention.
* Abrupt discontinuation after prolonged use can lead to adrenal insufficiency; a gradual tapering may be necessary.
* The effectiveness and safety profile can vary, and individual patient response is important.
* Due to potential teratogenicity, strict contraception measures are essential for women of childbearing potential.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant literature for complete details, and exercise clinical judgment when making treatment decisions. Local protocols may influence dosing and management.
